ILAE International League Against Epilepsy
    
 Login
 Search search
 Contact Us

 
Ilae Facebook Ilae Twitter

View ILAE in:

Arabic  Arabic
Chinese  中文版
French  Français
German  Deutsch
Spanish  Español
Italian  Italiano
Japanese  日本語
Portugese  Português

 
Epilepsia Report

Executive Summary

The 2004 year was successful for Epilepsia in several regards. We received more manuscript submissions than in prior years with the current editor, totaling 971. The mechanics of the editorial process and journal production have continued to improve, with fewer editorial, publication and circulation errors. Every issue has been printing within its cover month, usually early in the month.

Robert S. Fisher
Editor-in-Chief

Elizabeth Durzy
Journal Publishing Manager

Editorial Issues

Impact Factor

* Data in this report is taken from the 2003 ISI Journal Citation Reports®. This data should be considered confidential material for internal use only and may not be distributed or published in any way.

  • The Journal’s Impact Factor increased from 3.21 in 2001, to 3.53 in 2002, to 3.55 in 2003.
  • Epilepsia continues to move up in the Clinical Neurology Journal Rankings, from 15th in 2001, to 14th in 2002, to 13th in 2003.

Robert S. Fisher
 
Elizabeth Durzy

  Clinical Neurology
Journal Rank 2003
Top 20 in
of 135
2003 Impact Factor
1 Brain 7.97
2 Ann Neurol 7.72
3 Neurology 5.68
4 Neurosci Biobehav Res 5.48
5 Stroke 5.23
6 J Neuropath Exp Neurol 5.01
7 Arch Neurol 4.68
8 Pain 4.56
9 Int J Neuropsychology 4.00
10 Current Opinion Neurol 3.92
11 Brain Pathology 3.84
12 Bipolar Disorders 3.66
13 Epilepsia 3.55
14 Sleep 3.54
15 Mental Retard Dev Dis 3.48
16 Neuro-Oncology 3.37
17 Lancet Neurology 3.07
18 J Neurol Neurosurg Psych 3.04
19 Neurogenetics 3.03
20 Neuropath Applied Neuro 3.02


-----------------------------------------------------------------------------------

Volume

In 2004, we received 714 manuscripts.

From 1/1/04 - 11/9/04: Year to date decisions

Fisher = 421
Moshe = 191
Perucca = 157
Jackson = 68
Seratosa = 46
MacLaghlan = 4
Bergey = 1

Time from submission to decision:

2001 = 77 days
2002 = 55 days
2003 = 46 days
2004 (YTD) = 38 days

Acceptance by Country (1/20 - 11/04), Sorted by Total

Country

Accepted

Rejected

Revision

Total

Accept Rate

Total

846

1251

1048

3145

26.9%

USA

290

260

325

875

33.1%

Germany

74

70

91

235

31.5%

Italy

57

80

83

220

25.9%

Japan

41

99

63

203

20.2%

Canada

61

53

59

173

35.3%

UK

45

53

53

151

29.8%

France

37

27

55

119

31.1%

Brazil

17

63

26

106

16.0%

Netherlands

30

33

33

98

30.6%

Turkey

11

54

19

84

13.1%

Korea , Rep

14

40

20

74

18.9%

Australia

20

25

21

66

30.3%

India

6

43

11

60

10.0%

Taiwan

12

25

21

58

20.7%

Spain

4

32

6

42

9.5%

Switzerland

11

14

15

40

27.5%

Finland

9

16

14

39

23.1%

Israel

9

18

11

38

23.7%

Hungary

11

15

10

36

30.6%

Austria

5

19

10

34

14.7%

Sweden

10

15

7

32

31.3%

Poland

8

9

13

30

26.7%

China

3

18

4

25

12.0%

Czech Rep

5

10

8

23

21.7%

Mexico

3

12

6

21

14.3%

Iran

3

13

4

20

15.0%

Belgium

2

11

6

19

10.5%

Argentina

1

14

1

16

6.3%

Norway

4

7

4

15

26.7%

Hong Kong

2

11

1

14

14.3%

Portugal

2

5

5

12

16.7%

Egypt

3

4

5

12

25.0%

Singapore

0

8

2

10

0.0%

Greece

2

7

1

10

20.0%

Denmark

1

5

4

10

10.0%

Lebanon

2

5

1

8

25.0%

Yugoslavia

2

3

1

6

33.3%

Jordan

1

3

2

6

16.7%

Oman

0

4

1

5

0.0%

New Zealand

2

1

2

5

40.0%

Scotland

1

2

1

4

25.0%

Russia

2

2

0

4

50.0%

Colombia

1

1

2

4

25.0%

 

Acceptance by Country, Sorted by Acceptance Rate
(for Countries with at least 25 submissions)

Country Accepted Rejected Revision Total Accept Rate
Total
846
1251
1048
3145
26.9%
Canada
61
53
59
173
35.3%
USA
290
260
325
875
33.1%
Germany
74
70
91
235
31.5%
Sweden
10
15
7
32
31.3%
France
37
27
55
119
31.1%
Netherlands
30
33
33
98
30.6%
Hungary
11
15
10
36
30.6%
Australia
20
25
21
66
30.3%
UK
45
53
53
151
29.8%
Switzerland
11
14
15
40
27.5%
Poland
8
9
13
30
26.7%
Italy
57
80
83
220
25.9%
Israel
9
18
11
38
23.7%
Finland
9
16
14
39
23.1%
Taiwan
12
25
21
58
20.7%
Japan
41
99
63
203
20.2%
Korea, Rep
14
40
20
74
18.9%
Brazil
17
63
26
106
16.0%
Austria
5
19
10
34
14.7%
Turkey
11
54
19
84
13.1%
China
3
18
4
25
12.0%
India
6
43
11
60
10.0%
Spain
4
32
6
42
9.5%

---------------------------------------------------------------------------------

Note: The citation count below is a year old, because this year’s is not yet available

Appendix A - Top 50 Articles Accessed via Synergy

Rank

Acc.

Article

Author

Year

Vol.

Iss.

Pg.

1

678

The Importance of Drug Interactions in Epilepsy Therapy

Philip N. Patsalos, Walter Froumlscher, Francesco Pisani, Clementina M. van Rijn

2002

43

4

365

2

529

GABAergic Mechanisms in Epilepsy

David M. Treiman

2001

42

s3

8

3

520

Adolescent Seizures and Epilepsy Syndromes

James W. Wheless, Howard L Kim

2002

43

s3

33

4

502

Epileptic Syndromes in Childhood: Clinical Features, Outcomes, and Treatment

Peter Camfield, Carol Camfield

2002

43

s3

27

5

444

Genetics of the Epilepsies

Samuel F. Berkovic, Ingrid E. Scheffer

2001

42

s5

16

6

438

Neonatal Seizures and Syndromes

Barry R. Tharp

2002

43

s3

2

7

429

American Epilepsy Society Proceedings

null

2002

43

s7

1

8

427

Treatment of Refractory Status Epilepticus with Pentobarbital, Propofol, or Midazolam: A Systematic Review

Jan Claassen, Lawrence J. Hirsch, L Ronald G. Emerson, Stephan A. Mayer

2002

43

2

146

9

424

Is It Status?

Richard P. Brenner

2002

43

s3

103

10

384

A Proposed Diagnostic Scheme for People with Epileptic Seizures and with Epilepsy: Report of the ILAE Task Force on Classification and Terminology

Jerome Engel Jr.

2001

42

6

796

11

379

Cognitive and Behavioral Effects of Epilepsy Treatment

David W. Loring, Kimford J. Meador

2001

42

s8

24

12

340

Generalized Epileptic Disorders: An Update

Massimo Avoli, Michael A. Rogawski, Giuliano Avanzini

2001

42

4

445

13

333

Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy

Stephen M. Dombrowski, Shailesh Y. Desai, Matteo Marroni, Luca Cucullo, Kris Goodrich, William Bingaman, Marc R. Mayberg, Ljiljana Bengez, Damir Janigro

2001

42

12

1501

14

328

Chromosomal Abnormalities and Epilepsy: A Review for Clinicians and Gene Hunters

Rita Singh, R. J McKinlay Gardner, Kathryn M. Crossland, Ingrid E. Scheffer, Samuel F. Berkovic

2002

43

2

127

15

307

null

null

2001

42

s7

1

16

306

Functional MRI of Language Processing: Dependence on Input Modality and Temporal Lobe Epilepsy

A. Carpentier, K. R. Pugh, M. Westerveld, C. Studholme, O. Skrinjar, J.L. Thompson, D. D. Spencer, R.T. Constable

2001

42

10

1241

17

306

Infantile Seizures and Epilepsy Syndromes

Douglas R. Nordli Jr.

2002

43

s3

11

18

305

Neural Networks in Human Epilepsy: Evidence of and Implications for Treatment

Susan S. Spencer

2002

43

3

219

19

295

Children Versus Adults: Pharmacokinetic and Adverse-Effect Differences

Gail D. Anderson

2002

43

s3

53

20

294

Epileptic Encephalopathy

Olivier Dulac

2001

42

s3

23

21

286

The Challenge of Treatment Selection for Epilepsy

Edward Faught, John M. Pellock

2001

42

s8

4

22

283

Epilepsy Surgery in Childhood

J. Helen Cross

2002

43

s3

65

23

281

Advances in Neuroimaging: Surgical Localization

Gregory D. Cascino

2001

42

1

3

24

277

Potassium Channels: How Genetic Studies of Epileptic Syndromes Open Paths to New Therapeutic Targets and Drugs

Edward C. Cooper

2001

42

s5

49

25

276

Channelopathies: Episodic Disorders of the Nervous System

Louis J. Ptacek, Ying-Hui Fu

2001

42

s5

35

26

262

Special Needs of the Adolescent with Epilepsy

Douglas R. Nordli Jr.

2001

42

s8

10

27

261

Basic Mechanisms of Psychotropic Drugs

Ulrich Ebert

2002

43

s2

2

28

258

Voltage-gated Sodium Channels in Epilepsy

Ruumldiger Koumlhling

2002

43

11

1278

29

257

Is Refractory Epilepsy Preventable?

Santiago Arroyo, Martin J. Brodie, Giuliano Avanzini, Christoph Baumgartner, Catherine Chiron, Olivier Dulac, Jacqueline A. French, José M. Serratosa

2002

43

4

437

30

254

Treatment of Benign Epilepsy Syndromes Throughout Life

L. James Willmore

2001

42

s8

6

31

250

Gabapentin versus Lamotrigine Monotherapy: A Double-blind Comparison in Newly Diagnosed Epilepsy

Martin J. Brodie, David W. Chadwick, Henning Anhut, Andreas Otte, Silke-Lo Messmer, Stephen Maton, Wilhelm Sauermann, Guta Murray, Elizabeth A. Garofalo

2002

43

9

993

32

249

The Management of Refractory Idiopathic Epilepsies

Emilio Perucca

2001

42

s3

31

33

244

Effectiveness of First Antiepileptic Drug

Patrick Kwan, Martin J. Brodie

2001

42

10

1255

34

241

Placebos, Placebo Effect, and the Response to the Healing Situation: The Evolution of a Concept

Yiannis G. Papakostas, Michael D. Daras

2001

42

12

1614

35

239

Pregnancy Registries in Epilepsy

Ettore Beghi, John F. Annegers

2001

42

11

1422

36

238

Intractable Epilepsy: Definition and Neurobiology

Jerome Engel Jr.

2001

42

s6

3

37

238

Continuous EEG Monitoring in the Intensive Care Unit

Mark L. Scheuer

2002

43

s3

114

38

237

Cell Death and Synaptic Reorganizations Produced by Seizures

Yehezkel Ben-Ari

2001

42

s3

5

39

236

Chronic Anterior Thalamus Stimulation for Intractable Epilepsy

Mojgan Hodaie, Richard A. Wennberg, Jonathan O. Dostrovsky, Andres M. Lozano

2002

43

6

603

40

231

Carbamazepine versus Valproate Monotherapy for Epilepsy: A Meta-analysis

Anthony G. Marson, Paula R. Williamson, Helen Clough, Jane L. Hutton, David W. Chadwick, on behalf of the Epilepsy Monotherapy Trial Group

2002

43

5

505

41

227

Genetic Identifiers of Epilepsy

Sunao Kaneko, Hiroto Iwasa, Motohiro Okada

2002

43

s9

16

42

225

Levetiracetam Psychosis in Children with Epilepsy

Eric H. Kossoff, Gregory K. Bergey, John M. Freeman, Eileen P. G. Vining

2001

42

12

1611

43

221

Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs

Edoardo Spina, Emilio Perucca

2002

43

s2

37

44

218

Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open-label Trial

Tracy A. Glauser, John M. Pellock, E. Martina Bebin, Nathan B. Fountain, Frank J. Ritter, Christof M. Jensen, W. Donald Shields

2002

43

5

518

45

218

Impact of Pediatric Epilepsy on the Family: A New Scale for Clinical and Research Use

Carol Camfield, Lynn Breau, Peter Camfield

2001

42

1

104

46

213

Clinical and Genetic Analysis of a New Multigenerational Pedigree with GEFS+ (Generalized Epilepsy with Febrile Seizures Plus)

Frédérique Gérard, Sandrine Pereira, Andrée Robaglia-Schlupp, Pierre Genton, Pierre Szepetowski

2002

43

6

581

47

212

Preliminary Results on Pregnancy Outcomes in Women Using Lamotrigine

Patricia Tennis, R. R. Eldridge

2002

43

10

1161

48

210

Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy

Elisabeth Gordon, Orrin Devinsky

2001

42

10

1266

49

209

Effects of Antiepileptic Drugs on Cognition

Albert P. Aldenkamp

2001

42

s1

46

50

207

Modeling Human Epilepsies in Mice

Jeffrey L. Noebels

2001

42

s5

11

 

Circulation

  • Total circulation is up over the same period last year by 27%.
  • Society subscriptions (mainly AES) have increased 13%, while individual and institutional
    subscriptions have decreased 8% and 12% respectively.
  • Online Only subscriptions increased 56% over the same period last year.
  • Ortho-McNeil is sponsoring the distribution of Epilepsia to 1500 AAN residents in 2004, while Novartis is sponsoring the distribution of Epilepsia to another 400 AAN residents.
  • Epilepsia has 2519 consortia subscriptions through September 2004.

Circ. Table 1.
Total Circulation through October 31, 2004

Subscriber Type
October 2004
October 2003
% Difference
Society      
US
2,242
1947
15%
Canada/Mexico
130
114
14%
Rest of World
572
537
7%
Total Society
2,944
2,598
13%
 
Individuals
US
37
43
-14%
Canada/Mexico*
1
2
-50%
Rest of World
156
165
-5%
Total Individuals
194
210
-8%
 
Institutions
US
182
205
-11%
Canada/Mexico
27
36
-25%
Rest of World
647
736
-12%
Total Institutions
856
977
-12%
 
Sponsorships
US
1900
800
138%
Canada/Mexico
0
0
-
Rest of World
0
13
-100%

Total Sponsorship
1900
813
134%
Complimentary
289
260
11%
GRAND TOTAL
6,183
4,858
27%


Production

  • Journal has published within 4 business days of the scheduled mail date (often prior to the scheduled mail date) 80% of the time. Issues always mailed within month, usually in first week.
  • For all issues and supplements, the Synergy version of the journal has been available ahead of print in a complete issue format.
  • Through October, we published a total of 1,358 pages, excluding supplements.
  • Published 923 supplemental pages through the
    October supplement.
Annual page budget -

Editorial: 2016
Total: 2304

Per Issue page budget - Editorial: 168
Total: 192

The biggest production problems have been transitional problems to off-shore typesetting, e.g., tiny fonts on the covers and some poor figure quality.

Supplements 2004

  1. Photosensitivity - Kasteleijn-Nolst Trenité. Sanofi- Synthelabo
  2. Neurobehavioral disorders in epilepsy - Devinsky - From an AES symposium with an unrestricted grant from GlaxoSmithKline
  3. Japan Epilepsy Society 35th Congress. Completed and in press.
  4. Neuroimaging: Advances and Applications. AES 2003 Annual Course, supported by AES
  5. Catastrophic Epilepsies of Childhood. Glauser - Supported by Eisai
  6. Pregabalin - From Molecule to Medicine - Ben- Menachem, Symposium in the 2003 International Epilepsy Symposium in Portugal, sponsored by Pfizer.
  7. American Epilepsy Society Abstracts.
    Sponsored by AES.
Home | Contact Us | Privacy & Security | Login | Sitemap

© 2014 International League Against Epilepsy